A prospective study in a larger cohort of advanced NSCLC patients treated with chemoimmunotherapy is further warranted to validate the use of peripheral CD4+ T cells as biomarkers that are truly predictive of prognosis. This evidence concerns the gene CD4 and non-small cell lung carcinoma.